HC Wainwright Has Positive Outlook for Harrow Q4 Earnings

Harrow, Inc. (NASDAQ:HROW - Free Report) - Investment analysts at HC Wainwright increased their Q4 2024 earnings estimates for shares of Harrow in a report released on Tuesday, March 18th. HC Wainwright analyst Y. Chen now expects that the company will earn $0.16 per share for the quarter, up from their prior forecast of ($0.07). HC Wainwright has a "Buy" rating and a $57.00 price objective on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow's Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.07 EPS and FY2025 earnings at $0.21 EPS.

Separately, B. Riley decreased their price objective on shares of Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a report on Wednesday, December 4th.

Harrow Stock Down 3.6 %

Shares of Harrow stock traded down $1.07 during trading on Friday, hitting $28.93. 431,396 shares of the stock traded hands, compared to its average volume of 493,794. The stock has a market cap of $1.03 billion, a P/E ratio of -30.78 and a beta of 0.69. The company has a fifty day moving average price of $29.41 and a two-hundred day moving average price of $38.31. Harrow has a twelve month low of $9.86 and a twelve month high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.

Remove Ads

Hedge Funds Weigh In On Harrow

A number of hedge funds have recently modified their holdings of HROW. Vanguard Group Inc. grew its holdings in shares of Harrow by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company's stock worth $62,809,000 after purchasing an additional 5,225 shares during the last quarter. Braidwell LP boosted its position in Harrow by 106.3% in the fourth quarter. Braidwell LP now owns 907,039 shares of the company's stock valued at $30,431,000 after buying an additional 467,401 shares in the last quarter. State Street Corp grew its stake in Harrow by 2.2% during the third quarter. State Street Corp now owns 730,973 shares of the company's stock worth $32,865,000 after buying an additional 15,554 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Harrow by 0.6% in the third quarter. Geode Capital Management LLC now owns 722,730 shares of the company's stock valued at $32,500,000 after acquiring an additional 3,960 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. raised its stake in shares of Harrow by 6.7% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company's stock valued at $22,301,000 after acquiring an additional 41,896 shares during the last quarter. 72.76% of the stock is owned by institutional investors and hedge funds.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.